Anaplastic lymphoma kinase as a therapeutic target

Expert Opinion on Therapeutic Targets

Volumn 16, Issue 11, 2012, Pages 1127-1138

  Kruczynski, Anna ^a   Delsol, Georges ^b   Laurent, Camille ^b   Brousset, Pierre ^b,c   Lamant, Laurence ^b,c  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^b CHU PURPAN   (France)

^c CANCER RESEARCH CENTER OF TOULOUSE   (France)

Author keywords

Anaplastic large cell lymphoma; Anaplastic lymphoma kinase; Chromosomal translocation; Gene amplification; Inflammatory myofibroblastic tumor; Mutation; Neuroblastoma; Non small cell lung carcinoma; Resistance; Tyrosine kinase; Tyrosine kinase inhibitors

Indexed keywords

AF 802; ANAPLASTIC LYMPHOMA KINASE; AP 26113; ASP 3026; ASP3026; CEP 37440; CEPHALON 2; CRIZOTINIB; GANETESPIB; LDK 378; NMS E 628; PROTEIN TYROSINE KINASE INHIBITOR; RETASPIMYCIN; TSR 011; TSR 012; UNCLASSIFIED DRUG; X 396;

ANAPLASTIC LYMPHOMA KINASE GENE; CARCINOGENESIS; DRUG TARGETING; HUMAN; LARGE CELL LYMPHOMA; LUNG NON SMALL CELL CANCER; MUTATIONAL ANALYSIS; NEOPLASM; NEUROBLASTOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; PLASMA CELL GRANULOMA; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; LIGANDS; NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84867493208     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2012.719498     Document Type: Review

References (104)

1. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994;263:1281-4
2. Shiota M, Fujimoto J, Semba T, et al. Hyperphosphorylation of a novel 80 kDa protein tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene 1994;9:1567-74
3. Iwahara T, Fujimoto J, Wen D, et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 1997;14:439-49
4. Webb TR, Slavish J, George RE, et al. Anaplastic lymphoma kinase: Role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer Ther 2009;9:331-56
5. Pulford K, Lamant L, Morris SW, et al. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood 1997;89:1394-404
6. Duyster JM, Bai RY, Morris SW. Translocations involving anaplastic lymphoma kinase (ALK). Oncogene 2001;20:5623-37
7. Donella-Deana A, Marin O, Cesaro L, et al. Unique substrate specificity of anaplastic lymphoma kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity. Biochemistry 2005;44:8533-42
8. Lee CC, Jia Y, Li N, et al. Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain. Biochem J 2010;430:425-37
9. Bilsland JG, Wheeldon A, Mead A, et al. Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications. Neuropsychopharmacology 2008;33:685-700
10. Stoica GE, Kuo A, Aigner A, et al. Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J Biol Chem 2001;276:16772-9
11. Stoica GE, Kuo A, Powers C, et al. Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J Biol Chem 2002;277:35990-9
12. Miyake I, Hakomori Y, Shinohara A, et al. Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines. Oncogene 2002;21:5823-34
13. Moog-Lutz C, Degoutin J, Gouzi JY, et al. Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin. J Biol Chem 2005;280:26039-48
14. Mourali J, Benard A, Lourenco FC, et al. Anaplastic lymphoma kinase is a dependence receptor whose proapoptotic functions are activated by caspase cleavage. Mol Cell Biol 2006;26:6209-22
15. Lee HH, Norris A, Weiss JB, et al. Jelly belly protein activates the receptor tyrosine kinase Alk to specify visceral muscle pioneers. Nature 2003;425:507-12
16. Mathivet T, Mazot P, Vigny M. In contrast to agonist monoclonal antibodies, both C-terminal truncated form and full length form of Pleiotrophin failed to activate vertebrate ALK (anaplastic lymphoma kinase)? Cell Signal 2007;19:2434-43
17. Chiarle R, Voena C, Ambrogio C, et al. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008;8:11-23
18. Swerdlow SH, Campo E, Harris NL, et al. Tumours of haematopoietic and lymphoid tissues. IARC Press; Lyon: 2008
19. Benharroch D, Meguerian-Bedoyan Z, Lamant L, et al. ALK-positive lymphoma: A single disease with a broad spectrum of morphology. Blood 1998;91:2076-84
20. Drexler HG, Gignac SM, von Wasielewski R, et al. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas. Leukemia 2000;14:1533-59
21. Morris SW, Xue L, Ma Z, et al. Alk+ CD30+ lymphomas: A distinct molecular genetic subtype of non-Hodgkin's lymphoma. Br J Haematol 2001;113:275-95
22. Tort F, Pinyol M, Pulford K, et al. Molecular characterization of a new ALK translocation involving moesin (MSN-ALK) in anaplastic large cell lymphoma. Lab Invest 2001;81:419-26
23. Lamant L, Gascoyne RD, Duplantier MM, et al. Non-muscle myosin heavy chain (MYH9): A new partner fused to ALK in anaplastic large cell lymphoma. Genes Chromosomes Cancer 2003;37:427-32
24. Bischof D, Pulford K, Mason DY, et al. Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol 1997;17:2312-25
25. Mason DY, Pulford KA, Bischof D, et al. Nucleolar localization of the nucleophosmin-anaplastic lymphoma kinase is not required for malignant transformation. Cancer Res 1998;58:1057-62
26. Lamant L, Dastugue N, Pulford K, et al. A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation. Blood 1999;93:3088-95
27. Colleoni GW, Bridge JA, Garicochea B, et al. ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion. inv(2) (p23q35). Am J Pathol 2000;156:781-9
28. Ma Z, Cools J, Marynen P, et al. Inv(2) (p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis. Blood 2000;95:2144-9
29. Touriol C, Greenland C, Lamant L, et al. Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK- positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like). Blood 2000;95:3204-7
30. Hernandez L, Bea S, Bellosillo B, et al. Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas: identification of a new TFG-ALK(XL) chimeric gene with transforming activity. Am J Pathol 2002;160:1487-94
31. Falini B, Mason DY. Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: Clinical value of their detection by immunocytochemistry. Blood 2002;99:409-26
32. Armstrong F, Duplantier MM, Trempat P, et al. Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells. Oncogene 2004;23:6071-82
33. Armstrong F, Lamant L, Hieblot C, et al. TPM3-ALK expression induces changes in cytoskeleton organisation and confers higher metastatic capacities than other ALK fusion proteins. Eur J Cancer 2007;43:640-6
34. Fujimoto J, Shiota M, Iwahara T, et al. Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). Proc Natl Acad Sci USA 1996;93:4181-6
35. Greco A, Fusetti L, Miranda C, et al. Role of the TFG N-terminus and coiled-coil domain in the transforming activity of the thyroid TRK-T3 oncogene. Oncogene 1998;16:809-16
36. Butti MG, Bongarzone I, Ferraresi G, et al. A sequence analysis of the genomic regions involved in the rearrangements between TPM3 and NTRK1 genes producing TRK oncogenes in papillary thyroid carcinomas. Genomics 1995;28:15-24
37. Bretscher A. Regulation of cortical structure by the ezrin-radixin-moesin protein family. Curr Opin Cell Biol 1999;11:109-16
38. Yonemura S, Hirao M, Doi Y, et al. Ezrin/radixin/moesin (ERM) proteins bind to a positively charged amino acid cluster in the juxta-membrane cytoplasmic domain of CD44, CD43 and ICAM-2. J Cell Biol 1998;140:885-95
39. Barreiro O, Yanez-Mo M, Serrador JM, et al. Dynamic interaction of VCAM-1 and ICAM-1 with moeisn and ezrin in a novel endothelial docking structure for adherent leukocytes. J Cell Biol 2002;157:1233-45
40. Ikebe M, Komatsu S, Woodhead JL, et al. The tip of the coiled-coil rod determines the filament formation of smooth muscle and nonmuscle myosin. J Biol Chem 2001;276:30293-300
41. Barreca A, Lasorsa E, Riera L, et al. Anaplastic lymphoma kinase in human cancer. J Mol Endocrinol 2011;47:R11-23
42. Singh RR, Cho-Vega JH, Davuluri Y, et al. Sonic hedgehog signaling pathway is activated in ALK-positive anaplastic large cell lymphoma. Cancer Res 2009;69:2550-8
43. Chiarle R, Simmons WJ, Cai H, et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nature Med 2005;11:623-9
44. Delsol G, Lamant L, Mariame B, et al. A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2;5 translocation. Blood 1997;89:1483-90
45. Shi M, Miron PM, Hutchinson L, et al. Anaplastic lymphoma kinase-positive large B-cell lymphoma with complex karyotype and novel ALK gene rearrangements. Hum Pathol 2011;42:1562-7
46. Gascoyne RD, Lamant L, Martin-Subero JI, et al. ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: Report of 6 cases. Blood 2003;102:2568-73
47. Laurent C, Do C, Gascoyne RD, et al. Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: A rare clinicopathologic entity with poor prognosis. J Clin Oncol 2009;27:4211-16
48. Ma Z, Hill DA, Collins MH, et al. Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 2003;37:98-105
49. Debelenko LV, Arthur DC, Pack SD, et al. Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor. Lab Invest 2003;83:1255-65
50. Freeman A, Geddes N, Munson P, et al. Anaplastic lymphoma kinase (ALK 1) staining and molecular analysis in inflammatory myofibroblastic tumours of the bladder: A preliminary clinicopathological study of nine cases and review of the literature. Mod Pathol 2004;17:765-71
51. Tsuzuki T, Magi-Galluzzi C, Epstein JI. ALK-1 expression in inflammatory myofibroblastic tumor of the urinary bladder. Am J Surg Pathol 2004;28:1609-14
52. Butrynski JE, D'Adamo DR, Hornick JL, et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med 2010;363:1727-33
53. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6
54. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703
55. Camidge DR, Doebele RC. Treating ALK-positive lung cancer-early successes and future challenges. Nat Rev Clin Oncol 2012;9:268-77
56. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131:1190-203
57. Takeuchi K, Choi YL, Togashi Y, et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 2009;15:3143-9
58. Togashi Y, Soda M, Sakata S, et al. KLC1-ALK: A Novel Fusion in Lung Cancer Identified Using a Formalin-Fixed Paraffin- Embedded Tissue Only. PLoS One 2012;7:e31323
59. Jung Y, Kim P, Jung Y, et al. Discovery of ALK-ptpn3 gene fusion from human non-small cell lung carcinoma cell line using next generation RNA Sequencing. Genes Chromosomes Cancer 2012;51:590-7
60. Salido M, Pijuan L, Martinez-Aviles L, et al. Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer. J Thorac Oncol 2011;6:21-7
61. Yamamoto M, Takeuchi K, Shimoji M, et al. Small non-mucinous bronchioloalveolar carcinoma with anaplastic lymphoma kinase immunoreactivity: A novel ALK fusion gene? Cancer Sci 2012;103:390-2
62. Lamant L, Pulford K, Bischof D, et al. Expression of the ALK tyrosine kinase gene in neuroblastoma. Am J Pathol 2000;156:1711-21
63. Miyake I, Hakomori Y, Shinohara A, et al. Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines. Oncogene 2002;21:5823-34
64. Osajima-Hakomori Y, Miyake I, Ohira M, et al. Biological role of anaplastic lymphoma kinase in neuroblastoma. Am J Pathol 2005;167:213-22
65. Chen Y, Takita J, Choi YL, et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008;455:971-4
66. George RE, Attiyeh EF, Li S, et al. Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays. PLoS One 2007;2:e255
67. Janoueix-Lerosey I, Lequin D, Brugieres L, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008;455:967-70
68. Mosse YP, Laudenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008;455:930-5
69. Wood AC, Laudenslager M, Haglund EA, et al. Inhibition of ALK mutated neuroblastomas by the selective inhibitor PF-02341066, in: 2009 ASCO Meeting Proceedings. J Clin Oncol 2009;27:15S
70. Matthay KK, George RE, Yu AL. Promising therapeutic targets in neuroblastoma. Clin Cancer Res 2012;18:2740-53
71. Schulte JH, Lindner S, Bohrer A, et al. MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells. Oncogene 2012;In press
72. Coffin CM, Cessna MH, Perkins S, et al. Expression of ALK 1 and p80 in inflammatory myofibroblastic tumour and its mimics. A study of 135 cases. Mod. Pathol 2002;15:931-8
73. Chan JKC, Lamant L, Algar E, et al. ALK+ histiocytosis: A novel type of systemic histiocytic proliferative disorder of early infancy. Blood 2008;112:2965-8
74. Sugawara E, Togashi Y, Kuroda N, et al. Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method. Cancer 2012;In press
75. Debelenko LV, Raimondi SC, Daw N, et al. Renal cell carcinoma with novel VCL-ALK fusion: New representative of ALK-associated tumor spectrum. Mod Pathol 2011;24:430-2
76. Lin E, Li L, Guan Y, et al. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res 2009;7:1466-76
77. Lipson D, Capelletti M, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 2012;18:382-4
78. Ren H, Tan ZP, Zhu X, et al. Identification of anaplastic lymphoma kinase as a potential therapeutic target in ovarian cancer. Cancer Res 2012;In press
79. Murugan AK, Xing M. Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK Gene. Cancer Res 2011;71:4403-11
80. Giuriato S, Foisseau M, Dejean E, et al. Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma/ leukemia. Blood 2010;115:4061-70
81. Milkiewicz KL, Ott GR. Inhibitors of anaplastic lymphoma kinase: A patent review. Expert Opin Ther Pat 2010;20:1653-81
82. Hallberg B, Palmer RH. ALK and NSCLC: Targeted therapy with ALK inhibitors. F1000 Med Reports 2011;3:21-9
83. Bang Y, Kwak EL, Shaw AT, et al. Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). J Clin Oncol 2010;28:18s
84. Ou S-HI. Crizotinib : A novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. Drug Design. Development and Therapy 2011;5:471-85
85. Ou S-HI. Crizotinib : A drug that crystallizes a unique molecular subset of non-small-cell lung cancer. Expert Rev Anticancer Ther 2012;12:151-62
86. Gambacorti-Passerini C, Messa C, Pogliani EM. Crizotinib in anaplastic large-cell lymphoma. N Eng J Med 2011;364:775-6
87. Shakespeare WC, Rivera VM, Wang F, et al. Discovery of potent and selective orally active inhibitors of anaplastic lymphoma kinase. Proc Am Assoc Cancer Res 2009;50:A3738
88. Grande E, Bolos M-V, Arriola E. Targeting ALK: A promising strategy for cancer treatment. Mol Cancer Ther 2011;10:569-79
89. Kuromitsu S, Mori M, Shimada I, et al. Anti-tumor activities of ASP3026 against EML4-ALK tumor models. Proc AACR-NCI-EORTC International Conference-Molecular Targets and Cancer Therapeutics 2011. A227
90. Li N, Michellys P-Y, Kim S, et al. Activity of a potent and selective phase I ALK inhibitor LDK378 on naive and crizotinib-resistant preclinical tumor models. Proc AACR-NCI-EORTC International Conference-Molecular Targets and Cancer Therapeutics 2011. B232
91. Sakamoto H, Tsukaguchi T, Hiroshima S, et al. CH542802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 2011;19:679-90
92. Lovly CM, Heuckmann JM, De Stanchina E, et al. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res 2011;71:4920-31
93. Ardini E, Menichincheri M, De Ponti C, et al. Characterization of NMS-E628, a small molecule inhibitor of anaplastic lymphoma kinase with antitumor efficacy in ALK-dependent lymphoma and non-small cell lung cancer models. Mol Cancer Ther 2009;8:A244
94. Ardini E, Menichincheri M, Banfi P, et al. In vitro and in vivo activity of NMS-E628 against ALK mutations resistant to XalkoriR. Proc AACR-NCI-EORTC International Conference-Molecular Targets and Cancer Therapeutics 2011. A232
95. Wilcoxen KM, Brake RL, Saffran D, et al. Characterization of a novel series of potent, selective inhibitors of wild type and mutant/fusion anaplastic lymphoma kinase. Proc Am Assoc Cancer Res 2012;72:A1795
96. Chen Z, Sasaki T, Tan X, et al. Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res 2010;70:9827-36
97. Normant R, Paez G, West KA, et al. The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models. Oncogene 2011;30:2581-6
98. Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012;18:1472-82
99. Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 2012;4:120ra17
100. Lovly CM, Pao W. Escaping ALK inhibition: Mechanisms of and strategies to overcome resistance. Sci Transl Med 2012;4:119-23
101. Choi YL, Soda M, Yamashita Y, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010;363:1734-9
102. Sasaki T, Okuda K, Zheng W, et al. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res 2010;70:10038-43
103. Faber AL, Johnson LJ, Thomas JE. ALK mutant-driven cell lines develop crizotinib resistance by secondary mutations and ALK-independent means. Proc Am Assoc Cancer Res 2012;72:A5595
104. Katayama R, Khan TM, Benes C, et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harbouring the fusion oncogene EML4-ALK. Proc Natl Acad Sci USA 2011;108:7535-40